Shattuck Labs (NASDAQ:STTK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Key Points

• Needham raised Shattuck Labs’ price target from $17 to $19 and maintained a “buy” rating, implying 177.78% potential upside from the $6.84 share price.
• Analyst sentiment is broadly positive, with a consensus “Buy” rating and an average price target of $13.00, although ratings range from “Strong Buy” to “Sell.”
• Shattuck Labs reported quarterly EPS of -$0.12, in line with estimates, and institutional investors own 58.74% of the company; major recent investors included BlackRock and Frazier Life Sciences Management.

Shattuck Labs (NASDAQ:STTK - Get Free Report) had its target price raised by research analysts at Needham & Company LLC from $17.00 to $19.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Needham & Company LLC's price target indicates a potential upside of 177.78% from the company's current price.

A number of other brokerages have also recently commented on STTK. JPMorgan Chase & Co. began coverage on Shattuck Labs in a research report on Friday, July 24th. They issued an "overweight" rating and a $10.00 price target on the stock. TD Cowen upgraded shares of Shattuck Labs to a "strong-buy" rating in a research note on Monday, August 24th. Jefferies Financial Group raised shares of Shattuck Labs to an "outperform" rating and set a $7.00 target price on the stock in a report on Friday, June 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Shattuck Labs in a research report on Friday, September 11th. Finally, Wall Street Zen downgraded shares of Shattuck Labs from a "buy" rating to a "hold" rating in a report on Saturday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $13.00.

Shattuck Labs Stock Up 0.3%

Shares of NASDAQ:STTK opened at $6.84 on Friday. Shattuck Labs has a 12-month low of $1.70 and a 12-month high of $8.33. The company's 50 day moving average price is $6.92 and its two-hundred day moving average price is $6.53. The firm has a market cap of $686.46 million, a PE ratio of -13.41 and a beta of 1.09.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.12). On average, research analysts expect that Shattuck Labs will post -0.45 EPS for the current year.

Institutional Trading of Shattuck Labs

Large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Shattuck Labs in the 2nd quarter valued at approximately $27,315,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Shattuck Labs during the 2nd quarter valued at approximately $26,025,000. NEXTBio Capital Management LP acquired a new position in Shattuck Labs during the 4th quarter worth approximately $11,497,000. Wellington Management Group LLP bought a new position in Shattuck Labs in the 2nd quarter valued at approximately $12,269,000. Finally, S&G Foundation bought a new position in Shattuck Labs in the 2nd quarter valued at approximately $3,024,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company's research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create bifunctional fusion proteins that combine immune-cell activation with the targeted blocking of immune-suppressive pathways.

Shattuck's lead investigational programs are intended to stimulate antitumor immune responses within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.